Company Overview and News

0
TSS / Total System Services, Inc. FORM SD

2018-05-28 sec.gov
Form SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TSS

102
IPO Coverage: EVO Payments, Inc.

2018-05-23 seekingalpha
EVO Payments (EVOP), a global merchant acquirer and payment processor, will IPO on Wednesday, May 23.
TSS DBX SPOT WP FDC GPN EVOP SNAP

25
Bitcoin Is Going to Sink Square Inc Stock. Here’s How

2018-05-17 investorplace
Square Inc (NASDAQ:SQ) CEO Jack Dorsey was welcomed like a conquering hero to the Consensus 2018 Bitcoin conference this week. The event at the New York Hilton drew 8,400 people at $2,000 per ticket, and Dorsey’s decision to support Bitcoin in Square’s Cash app was the star of the show. This news has been very good for Square stock.
TSS V SQ SQNXF PYPL

14
IPO Of Evo Payments: The Goodwill Represents An Opportunity

2018-05-16 seekingalpha
The company is trying to sell 14 million shares at $14-$16. I believe that the price is low as compared to peers.
TSS NDAQ WP FDC GPN

0
TSS / Total System Services, Inc. FORM 424(B)(2) (Prospectus)

2018-05-11 sec.gov
Form 424(b)(2) Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-210148 CALCULATION OF REGISTRATION FEE
TSS

0
TSS / Total System Services, Inc. FORM 8-K (Current Report)

2018-05-11 sec.gov
Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TSS

0
TSS / Total System Services, Inc. FWP

2018-05-09 sec.gov
FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-210148 Pricing Term Sheet
TSS

0
TSS / Total System Services, Inc. 424B3 (Prospectus)

2018-05-09 sec.gov
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-210148 The information in this Preliminary Prospectus Supplement is not complete and may be changed. This Preliminary Prospectus Supplement and the accompanying Prospectus do not constitute an offer to sell these secu
TSS

26
MoneyGram (MGI) Q1 Earnings and Revenues Miss, Fall YoY

2018-05-09 zacks
MoneyGram International Inc. (MGI - Free Report) reported earnings of 9 cents per share, missing the Zacks Consensus Estimate by 52.6% and declining 133% year over year.
TSS MGI ADS

0
TSS / Total System Services, Inc. 10-Q (Quarterly Report)

2018-05-08 sec.gov
tss_Current_Folio_10Q Table of Contents <
TSS

38
Mastercard’s Gross Dollar Volumes

2018-05-08 marketrealist
In 1Q18, Mastercard (MA) reported total gross dollar volumes of $1.41 trillion, which reflects a rise of 14% on a YoY (year-over-year) basis. Of the total gross dollar volumes in 1Q18, the US region contributed $419 billion. In 1Q17, the US region contributed $379 billion. The total gross dollar volumes reflected a 10% rise due to 9% credit growth and 12% debit growth.
TSS COF.PRG COF.PRH COF-P COF.WS COF.PRP COF COF-D COF-C COF-F GPN COF.PRC COF.PRD COF.PRF

33
Global Payments (GPN) Tops Q1 Earnings, Raises Guidance

2018-05-03 zacks
Global Payments Inc. (GPN - Free Report) came up with first-quarter 2018 adjusted earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.09 and surging nearly 33% year over year.
TSS V RSG GPN ADS

59
Western Union (WU) Beats on Q1 Earnings, Updates 2018 View

2018-05-02 zacks
The Western Union Company (WU - Free Report) reported first-quarter 2018 operating earnings per share of 45 cents, which surpassed the Zacks Consensus Estimate by 7.1%. The bottom line also improved 28.6% year over year on higher revenues, lower tax and reduction in share count.
TSS WFC WFCNP WFC.WS WU WFC.PRL WFC.PRJ WFC.PRT WFC.PRR V WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX ADS WFC.PRW WFC.PRV

57
Mastercard (MA) Q1 Earnings Beat on Volume Growth, Shares Up

2018-05-02 zacks
Mastercard Incorporated (MA - Free Report) reported first-quarter adjusted earnings per share of $1.50 per share, beating the Zacks Consensus Estimate of $1.26. Earnings improved 43% year over year (on a currency neutral basis).
TSS WFC WFCNP WFC.WS WFC.PRL MA WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX ADS WFC.PRW WFC.PRV

1
TSS / Total System Services, Inc. FORM 8-K (Current Report)

2018-04-27 sec.gov
Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TSS

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSS / Total System Services, Inc. on message board site Silicon Investor.

Total System Services, Inc. (TSS) Tissera (TSSR)
TouchStone S/W (TSSW) TSSP ��� Trendsetter Solar Products, Inc. (Bulls Board)
VTSS: Vitesse Semiconductor TSSA Tessa Complete Health Care
TSSL Is TOTAL SERVICE SYSTEMS (TSS) overvalued ?
VTSS-Cabot Market Letter Recommendation @34
CUSIP: 891906109